natgillin/translations-raw huggingface dataset:
Ann Neurol. 55, 164-173. An in vivo method for detecting a-synuclein protofibrils in human tissue, comprising administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and a-synuclein protofibrils in the human tissue, wherein the antibody or fragment thereof has high affinity for human a-synuclein protofibrils and low affinity for a-synuclein monomers and has a combination of three variable heavy (VH) CDR sequences and three variable light (VL) CDR sequences selected from the following combinations: 
Protutijelo, ili njegov fragment, naznačeno time što se veže na ljudski a-sinukleinski protofibrili molekulske težine u rasponu od 1000 do 5000 kDa, gdje vezanje protutijela, ili fragmenta, na svaki od a-sinukleinskih monomera i f-sinukleinskih monomera je najmanje 100 puta slabije od vezanja protutijela, ili fragmenta, na ljudske a-sinukleinske protofibrile, gdje protutijelo, ili fragment, ima tri varijabilna teška (VH) CDR slijeda (VH- CDR-1, VH-CDR-2, te VH-CDR-3) i tri varijabilna laka (VL) CDR slijeda (VL-CDR-1, VL-CDR-2, te VL-CDR3), te gdje protutijelo, ili njegov fragment, ima kombinacija CDR sljedova koju se bira između sljedećih kombinacija:
characterized in that HFA 134a is the sole propellant and formoterol fumarate dihydrate is suspended in a micronised form in the formulation while beclometasone dipropionate is fully dissolved. 
naznačena time da je 1,1,1,2-tetrafluoretan jedini propelant te da je formoterol-fumarat dihidrat suspendiran u formulaciju usitnjenom obliku, dok je beklometazon-dipropionat potpuno otopljen.
a number of injection unit (251) corresponding to a multiple of the cylinder number in the engine, and which are connected with each their dosing cylinder with a dosing piston (21); a supply line for cylinder lubricating oil; 
"niz jedimica za ubrizgavanje (251) koje odgovaraju višekratniku broja cilindara u motoru i kojo su povezane svaka sa svojim dozirnim cilindrom s dozirnim klipom (21), dovodna hnija za mazivo ulje za cilindar;
The method of claim 11, wherein the wound is selected from the group consisting of a burn, trauma, hard to heal and a chronic wound. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 8, gdje je rana odabrana iz skupine koja se sastoji od opekotine, traume, rane koja teško zarasta i kronične rane.
after the absorption of said predetermined amount of energy (Ev) validate the candidate signal (Sc) if its residual content of energy exceeds a predetermined threshold: characterized by said control means being further adapted to: 
nakon apsorbiranja navedene zadane količine energije (E,) provjeri kandidatnog signala (S.) prelazi li njegov preostali sadržaj energije zadani prag: naznačen time što je navedeni upravljački sklop dodatno prilagođen za:
The long term evolution network of anyone of the claims 8 to 12, wherein the special data packet received by the target eNB comprises a packet data convergence protocol, PDCP, sequence number, having a value of a PDCP sequence number of the last user data packet that has been sent through the X2 interface adding 1. 
Evoluirani ČvorB, eNB, koji je ciljni eNB, pri čemu, u fazi završetka primopredaje između izvorišnog eNB i ciljnog eNB bez uključivanja osnovne mreže u mreži dugoročne evolucije, LTE,, naznačen time da eNB sadrži: jedinicu za prijem korisničkih podataka (1210), konfiguriranu za prijem paketa korisničkih podataka dostavljenih od poslužiteljskog pristupnika, SGW;
The results obtained show that the MEP HYPERCEL® resin, efficiently captures the beta-galactosidase enzyme from the solution. 
Dobiveni rezultati pokazali su da smola MEP HyperCel efikasno hvata enzim beta-galaktozidazu iz otopine.
The invention also provides a kit of parts comprising (b) an M3 antagonist of the invention together with instructions for simultaneous, concurrent, separate or sequential use in combination with (a) a corticosteroid,l for the treatment of a human or animal patient suffering from or susceptible to a said respiratory disease. 
Predmetni izum također omogućuje proizvodnju pribora s dijelovima koji sadrži (b) M3 antagonist sukladno predmctnom izumu zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijainu uporabu u kombinaciji s (a) B2 agonistom, za liječenje bolesnih ljudi ili životinja koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti koja odgovara na M3 antagonizam.
The invention further relates to coating compositions comprising fatty acids or derivatives thereof as well as substrates with coatings obtained by heat curing of such coating compositions. 
Izum se odnosi, nadalje, na sastav premaza koji sadrži masne kiseline ili njihove derivate, kao također i na podloge s prevlakama koje su dobivene toplinskim otvrdnjavanjem takovih sastava premaza.
A container containing a solution as claimed in claim 14, wherein the container contains 25ml, 100ml, 150ml, 250ml or 500ml of solution. A container as claimed in claim 14 containing: 
Spremnik, naznačen time što sadrži otopinu u skladu s patentnim zahtjevom 14, naznačen time što spremnik sadrži 25 ml, 100 ml, 150 ml, 250 ml ili 500 ml otopine.
After refluxing the reaction mixture for 30 minutes, it was cooled to room temperature and concentrated in vacuo. 
Nakon refluksiranja reakcijske smjese tijekom 30 minuta, ohladi se na sobnu temperaturu te koncentrira in vacuo.
Process according to Claim 1, characterized in that during step b), said gas mixture is washed and dried, thus producing a dry gas mixture. 
Postupak prema zahtjevu 1, naznačen time da tijekom koraka b), navedena plinska mješavina je isprana i osušena, to se tako dobiva suha plinska mješavina.
The aqueous pharmaceutical suspension according to claim 1, wherein the preservative system further comprises about 0.06% to about 0.26% of edetate disodium, about 0.01% to about 0.27% of benzoic acid or sodium benzoate, about 0.01% to about 0.30% of sorbic acid or potassium sorbate or about 0.10% to about 1.50% of benzyl alcohol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što sustav konzervansa dodatno sadrži otprilike 0,06 % do otprilike 0,26 % dinatrijevog edetata, otprilike 0,01 % do otprilike 0,27 % benzojeve kiseline ili natrijevog benzoata, otprilike 0,01 % do otprilike 0,30 % sorbinske kiseline ili kalijevog sorbata ili otprilike 0,10 % do otprilike 1,50 % benzil-alkohola.
a protein-binding segment that interacts with the Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein the target DNA is present in a single-cell eukaryotic organism, a fungal cell, an animal cell, or a plant cell, wherein said modifying is cleavage of the target DNA, wherein: said contacting is in vitro or in a cell ex vivo; and/or 
(ii) segment koji veže protein i koji međudjeluje s navedenim kimernim proteinom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziraju za tvorbu dvostruke RNK strukture (AdsRNK)-dupleks, gdje se navadeno stavljanje u doticaj provodi in vitro ili u stanici ex vivo. Postupak moduliranja polipeptida koji je povezan s ciljanom DNK, naznačen time, da postupak obuhvaća stavljanje u doticaj ciljane DNK s kompleksom koji obuhvaća sljedeće:
A method of inhibiting the interaction of a human beta7 integrin subunit with a second integrin subunit and/or a ligand in vitro, by contacting the humanized anti-beta7 antibody of any one of claims 1 to 15 with the beta7 integrin. 
Postupak inhibiranja interakcije humane beta7 integrinske podjedinice s drugom integrinskom podjedinicom i/ili s ligandom in vitro, naznačen time, da se vrši stupanjem u vezu anti-beta7 protutijela prema bilo kojem zahtjevu 1 do 21, s beta7 integrinom.
The titled compound was prepared analogously to 4-cyano-3-ethoxy-benzenesulfonyl chloride (Intermediate 127c) by replacing bromoethane with 1-bromobutane. 
Naslovni spoj je proizveden analogno 4-cijano-3-etoksi-benzensulfonil kloridu (intermedijat 127c) zamjenom bromoetana s 1-brombutanom.
The suspension is allowed to cool to room temperature and isolated by vacuum filtration. 
Suspenziju se ostavi da se ohladi do sobne temperature, te izdvoji vakuumskom filtracijom.
lipophilic extract of Zingiber officinale, and lipophilic extract of Echinacea angustifolia, obtainable by extraction with carbon dioxide under supercritical conditions, for the preparation of a composition for the prevention and treatment of oesophageal reflux. 
Upotreba: a) lipofilnog ekstrakta Zingiber officinale, te b) lipofilnog ekstrakta Echinacea angustifolia, koji se dobivaju ekstrakcijom s ugljičnim dioksidom pri superkritičnim uvjetima, naznačena time da je za preparaciju pripravaka za prevenciju 1 liječenje gastroezofagealne refluksne bolesti.
The composition of claim 9, wherein the lower alkyl alcohol is selected from the group consisting of ethanol, propanol, isopropyl alcohol, and mixtures thereof. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je niži alkil alkohol izabran iz skupine koja se sastoji od etanola, propanola, izopropil alkohola i njihovih smjesa.
providing a structure (F) with at least four frame-members (H 1, H 2, H 3, H 4); 
(a) izrada okvirne konstrukcije (F) s najmanje četiri okvirna elementa (H,, H>, H;, Hy);
followed by a de-complexation step in which the optionally substituted cyclopentadienyliron is de-complexed to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine (vortioxetine). 
UV] nakon čega slijedi korak de-kompleksacije u kojem se po izboru supstituirani ciklopentadieniliron de-kompleksira da se dobije 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazin (vortioksetin).
The composition according to claim 1, wherein the GPR119 agonist is an agonist of human GPR119, and the DPP-IV inhibitor is an inhibitor of human DPP-IV. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119, te DPP-IV inhibitor je inhibitor humanog DPP-IV.
Alternatively, the Applicant describes and claims the possible combination of the two components (HA derivatives and CS) at the time of use, that is, just before the intra-articular or locoregional or intrabladder treatment, or, as a further alternative, the separate administration of the two components which combine directly within the treatment site. 
Magistarska viskozna maziva namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačena time što se CS kombinira s derivatom HA neposredno prije intraartikularne ili lokoregionalne primjene ili izravno na mjestu primjene nakon odvojene primjene dviju komponenti.
A sealable container according to embodiment 7, wherein the distance between the upper surface of the denesting area and the base of the tray is shorter than the distance between the upper surface of the flange and the base. 
Posuda prema bilo kojem od prethodnih Zahtjeva, gdje je razmak između gornje površine područja za razdvajanje posuda i osnove plitke posude kraće od razmaka između gornje površine prirubnice i osnove.
A process for preparing a compound of formula II, comprising deprotecting a compound of formula III: 
Postupak dobivanja spoja formule II, naznačen time što se sastoji u uklanjanju zaštite sa spoja formule III:
A method according to claim 1 for the treatment of Phytophtora, Monilia, Penicillium sp, Geotrichum sp, Rhizoctonia, Helminthosporium, Cholletotrichum. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time što je za tretiranje Phytophtora, Monilia, Penicillium sp, Geotrichum sp, Rhizoctonia, Helminthosporium, Cholletotrichum.
The dosage form according to any of the preceding claims, wherein oxycodone and/or naloxone are present in the form of a pharmaceutically acceptable salt. The dosage form according to claim 7, wherein oxycodone and/or naloxone are present in the form of a hydrochloride, sulfate, bisulfate, tartrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate. 
Farmaceutski oblik doziranja prema patentnom zahtjevu 1 za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje, gdje je navedena farmaceutski prihvatljiva sol hidroklorid, sulfat, bisulfat, tartrat, nitrat, citrat, bitatrat, fosfat, malat, maleat, hidrobromid, hidroiodid, fumarat ili sucinat.
is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; 
je atom vodika, izborno supstituirana alkil grupa, izborno supstituirana alkenil grupa, izborno supstituirana aril grupa ili izborno supstituirana heteroaril grupa;
The compounds will typically be administered in amounts that are therapeutically or prophylactically useful and which generally are non-toxic. 
Spojevi će se općenito primijeniti u količinama koje su terapeutski ili profilaktički korisne i koje općenito nisu toksične.
The plough in accordance with claim 8, wherein the abutment surface is single-curved around an axis which is parallel to the longitudinal axis of the plough point. 
Lemeš (2) u skladu sa zahtjevom 4, naznačen time da je potporna površina (42) jednostruko zakrivljena oko osi koja je paralelna s uzdužnom osi (SA) vrha pluga (3).
Analgecine for use as a medicament for the treatment of an acute ischemic cerebrovascular disease, wherein after ischemia of brain tissue analgecine is used for protecting a nerve cell from injury or for decreasing the level of lactic acid in brain tissue or for increasing the activity of superoxide dismutase and wherein the acute ischemic cerebrovascular disease is selected from the group consisting of cerebral embolism, transient cerebral ischemia attack, cerebral thrombosis, cerebral arteriosclerosis, cerebral arteritis, steal syndrome of cerebral artery, cranial venous sinus and venous thrombus. 
Analgecine za uporabu kao lijek za liječenje akutne ishemijske cerebrovaskularne bolesti, gdje se nakon ishemije moždanog tkiva analgecine koristi za zaštitu živčanih stanica od ozljede ili za smanjenje razine mliječne kiseline u moždanom tkivu ili za povećanje aktivnosti superoksid dismutaze, i gdje se akutna ishemijska cerebrovaskularna bolest odabire iz skupine koju čine cerebralna embolija, tranzitna cerebralna ishemijska ataka, cerebralna tromboza, cerebralna arterioskleroza, cerebralni arteritis, sindrom krađe cerebralne arterije, kranijalni venski sinus i venski tromb.
A process as in Claim 2, wherein the compound of formula (VI) is reacted with a zinc salt; wherein the zinc salt is zinc dibromide and wherein the zinc dibromide is present in an amount in the range of from about 0.33 to about 1.0 molar equivalents. 
Postupak kao u patentnom zahtjevu 2, naznačen time da spoj formule (VI) reagira s cinkovom soli; pri čemu cinkova sol je cink dibromid i pri čemu je cink dibromid prisutan u količini u rasponu od oko 0.33 do oko 1.0 molarnih ekvivalenata.
Said condensation system preferably comprises the shell-side of one or more shell-and-tube heat-exchangers. 
Pogon prema zahtjevu 9, pri čemu kondenzacijski sustav obuhvaća ljusku jednog ili više izmjenjivača topline cijev u cijev.
ARC, in combination w/TNF (tumor necrosis 
ARC, u kombinaciji w/TNF (faktor nekroze tumora)
A container according to claim 7, characterized in that the separate ring-formed element forming the fluid collecting lip (7) is provided with downwardly protruding reinforcing ribs (13). 
Spremnik prema zahtjevu 6, naznačen time što posebni element u obliku prstena koji formira rub za skupljanje tekućine (7) ima potporna rebra koja se pružaju prema dolje (13).
of sodium thiomethoxide (1.1 g, 16 mmol) was added, and the reaction mixture was heated to 100° C. under nitrogen for 1 hour. 
natrijevog tiometoksida (1,1 g, 16 mmmol), a reakcijsku smjesu grije 1 sat na 100 "C u atmosferi dušika.
The method of claim 15, wherein the recombinant nucleic acid coding for a VKD protein is stably expressed. 
Postupak prema zahtjevu 15, naznačen time, da se stabilno eksprimira rekombinantna nukleinska kiselina, koja kodira za VKD-protein.
Inhaler device (1) of a powdered substance contained in a capsule (2) of the type having an operculum formed of two parts, comprising: 
PATENTNI ZAHTJEVI Aparat za inhalaciju (1) praškaste konzistencije sadržane u kapsuli (2) tipa koji ima poklopac sastavljen iz dva dijela koji obuhvaća:
A compound according to claim 1 selected from the group consisting of, and or having the structure or 
Tvar u skladu s patentnim zahtjevom 1 odabrana iz grupe koja se sastoji od I >
defining a first fluid path along the path of said first fluid stream; defining a second fluid path at about a right angle to said first path that intersects with said first fluid path and does not continue past said first fluid path to form an intersection of said first and second fluid paths; 
određivanje prve fluidne putanje uzduž putanje od navedenog prvog fluidnog toka; određivanje druge fluidne putanje uz otprilike pravi kut prema navedenoj prvoj putanji koja se siječe s navedenom prvom fluidnom putanjom i ne nastavlja prolaziti uz navedenu prvu fluidnu putanju, kako bi se oblikovalo sjecište od prve i druge fluidne putanje;
The compound of claim 1 in free form or in pharmaceutically acceptable salt form, in at least 98% enantiomeric excess. 
obnavljanje tako dobivenog spoja formule (I) u slobodnom obliku ili u obliku farmaceutski prihvatljive soli.
heating the composite film (1) up to an activation temperature of between 165 to 175°C during 1.5 to 3 s in order to permanently bond the membrane (20) to the support layer (30). 
zagrijavanje kompozitne folije (1) do temperature aktiviranja između 165 do 175 °C tijekom 1,5 do 3 s kako bi se trajno vezala membrana (20) na nosivi sloj (30).
50 20 A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of (A) a compound of formula I 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule
The motorized buoy of claim 1, further including a beacon for providing a visual signal. 
Motorizirana bova prema zahtjevu 1, naznačena time, da nadalje obuhvaća radiosvjetionik za odašiljanje vizualnog signala.
Preferably, the spring 15 is located within the metering chamber 6 . 
Ponajprije, opruga 15 se nalazi unutar odmjerne komore 6.
The samples were prepared by weighing approximately 30 mg asenapine maleate in a centrifugal tube and adding 2 ml of the dispersion liquid. 
Uzorci su pripremljeni vaganjem otprilike 30 mg asenapin maleata u epruveti za centrifugiranje i dodavanjem 2 ml tekućine za disperziju.
The dispensing valve 30 may optionally be provided at the free end of the dispensing tube 10. 
Ventil za točenje 30 može se prema potrebi predvidjeti na slobodnom kraju cijevi za točenje 10.
The LNG fuel tank system according to claim 5, wherein propulsion gas from the gas vessel is supplied via a gas line passing a heater. 
Sustav spremnika za LNG gorivo prema zahtjevu 5, naznačen time da se pogonski plin iz spremnika plina (8) dovodi putem plinskog voda (11) koji prolazi grijač (13).
The portable cooking and delivery system of claim 1 wherein the heating elements of at least one of ovens is an electric heating element. The portable cooking and delivery system of claim 1 wherein at least one of the ovens includes an actuator moveable between a retracted configuration and an expanded configuration, wherein movement of the actuator from the retracted configuration to the expanded configuration moves the contents of the oven out of the oven without the contents being touched by a human. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje koji je pomičan između uvučene konfiguracije i rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pomicanje uređaja za izbacivanje (246) iz uvučene konfiguracije prema rastegnutoj konfiguraciji, u svrhu pomicanja sadržina štednjaka izvan štednjaka, bez doticaja ljudskih ruku sa sadržajem.
DETAILED DESCRIPTION OF ASPECTS OF THE INVENTION 
Datum podnošenja europske prijave patenta:
The system for fixing profiles (2) according to claims 3 and 4 characterized in that the fastener (6) is suitable for attaching to the fastening element (4) and to the profiles (2). 
Sustav za učvršćivanje profila (2) prema zahtjevima 3 i 4 naznačen time da je spona (6) prikladna za pričvršćivanje na element za učvršćivanje (4) i na profile (2).
Sample for chemical and microbiological testing. 
Uzorak za kemijsko i mikrobiološko testiranje.
A dose counter as claimed in Claim 3 in which the first shaft is mounted for rotation relative to a substantially rotationally fixed element of the dose counter. 
Brojač doze (36) za inhalator, brojač doze (36) ima sklop osovine (110) i brojevne vrpce (112) prema zahtjevu 10.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
exhibits overexpression, translocation, amplification, or rearrangement of a myc family oncoprotein; 
je povezan s prekomjernom ekspresijom, translokacijom, amplifikacijom, ili rearanžmanom proteina BET;
the part of the gas spring inserted into the gas spring connecting unit is connected by means of at least one of a cylindrical pin extending through an opening of the inserted gas spring part and housing at least one U-shaped clip arranged in a form-fitting manner in a slot in the inserted part of the gas spring. The device as claimed in claim 15, wherein 
je dio plinske opruge (1) koji se umeće u spojnu jedinicu plinske opruge (70) spojen pomoću barem jednog cilindričnog klina koji se proteže u zazor umetnute gas plinske opruge i kućišta (20) ili pomoću barem jedne spojnice U-oblika smještene u utor u umetnutom dijelu plinske opruge (1) spajanjem pomoću oblika.
The method as claimed in claim 2, wherein the paper is a thin raw paper with a weight of about 40-50 g/m2. 
Metoda u skladu sa patentnim zahtjevom 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 50 g/m2.
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which is halogen, or 1-4C-alkyl, 
Harl je izborno supstituiran s R6111 i/ili R6112 i monociklički je ili kondenzirani biciklički 5- do 10-eročlani nezasićeni heteroaromatski prsten, koji sadrži jedan do tri heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, gdje R6111 je halogen ili 1-4C-alkal, R6112 je 1-4C-alkil, 1
E-32. A crystal structure of or as defined in Embodiment 2. 
Kristalna struktura kako je definirano u zahtjevu 1 naznačena time da ima formulu Ia